Lupin gets USFDA nod for generic diabetes drug

PTI New Delhi | Updated on January 07, 2021 Published on January 07, 2021

Drug maker Lupin on Thursday said it has received approval from the US health regulator for its Empagliflozin and Metformin Hydrochloride extended-release (ER) tablets, used to treat diabetes, in the American market.

The company has received tentative approval for the product in multiple strengths from the United States Food and Drug Administration (USFDA), Lupin said in a statement.

The Mumbai-based company's product is a generic equivalent of Boehringer Ingelheim Pharmaceuticals' Synjardy XR tablets, it added.

The product will be manufactured at Lupin's Nagpur-based manufacturing facility.

Empagliflozin and Metformin Hydrochloride extended-release (ER) tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus treatment with both empagliflozin and metformin hydrochloride is appropriate.

As per IQVIA MAT November 2020 data, Empagliflozin and Metformin Hydrochloride ER Tablets had estimated annual sales of $357 million in the US.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on January 07, 2021
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.